Top

Published in:

01-07-2017 | Review

Cytokine storm and sepsis disease pathogenesis

Authors: Benjamin G. Chousterman, Filip K. Swirski, Georg F. Weber

Published in: Seminars in Immunopathology | Issue 5/2017

Abstract

Infectious diseases are a leading cause of death worldwide. Sepsis is a severe clinical syndrome related to the host response to infection. The severity of infections is due to an activation cascade that will lead to an autoamplifying cytokine production: the cytokine storm. Cytokines are a broad category of relatively small proteins (<40 kDa) that are produced and released with the aim of cell signaling. Our understanding of the processes that trigger this tremendous amount of cytokine production has made dramatic progress over the last decades, but unfortunately, these findings could not translate yet into effective treatments; so far, all clinical trials targeting cytokine production or effects failed. This review aims to summarize the pathophysiology of the cytokine storm; to describe the type, effects, and kinetics of cytokine production; and to discuss the therapeutic challenges of targeting cytokines. New promising therapeutic strategies focusing on the endothelium, as a source and a target of cytokines, are described.

Ferrara JL, Abhyankar S, Gilliland DG (1993) Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1. Transplant Proc 25(1 Pt 2):1216–1217PubMed

Yokota S (2003) Influenza-associated encephalopathy—pathophysiology and disease mechanisms. Nihon Rinsho 61(11):1953–1958PubMed

Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG (2012) Into the eye of the cytokine storm. Microbiol Mol Biol Rev 76(1):16–32. doi:10.1128/MMBR.05015-11 PubMedPubMedCentralCrossRef

Bone RC, Sibbald WJ, Sprung CL (1992) The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 101(6):1481–1483PubMedCrossRef

Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC (2016) The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315(8):801–810. doi:10.1001/jama.2016.0287 PubMedPubMedCentralCrossRef

Fleischmann C, Scherag A, Adhikari NK, Hartog CS, Tsaganos T, Schlattmann P, Angus DC, Reinhart K, International Forum of Acute Care T (2016) Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med 193(3):259–272. doi:10.1164/rccm.201504-0781OC PubMedCrossRef

Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS (2010) Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 362(23):2155–2165. doi:10.1056/NEJMoa0908610 PubMedCrossRef

Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29. doi:10.3322/caac.21208 PubMedCrossRef

Adhikari NK, Fowler RA, Bhagwanjee S, Rubenfeld GD (2010) Critical care and the global burden of critical illness in adults. Lancet 376(9749):1339–1346. doi:10.1016/S0140-6736(10)60446-1 PubMedCrossRef

10.

Janeway CA Jr, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20:197–216. doi:10.1146/annurev.immunol.20.083001.084359 PubMedCrossRef

11.

Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124(4):783–801. doi:10.1016/j.cell.2006.02.015 PubMedCrossRef

12.

Netea MG (2013) Training innate immunity: the changing concept of immunological memory in innate host defence. Eur J Clin Investig 43(8):881–884. doi:10.1111/eci.12132 CrossRef

13.

Netea MG, Quintin J, van der Meer JW (2011) Trained immunity: a memory for innate host defense. Cell Host Microbe 9(5):355–361. doi:10.1016/j.chom.2011.04.006 PubMedCrossRef

14.

Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA (1996) The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86(6):973–983PubMedCrossRef

15.

Medzhitov R, Preston-Hurlburt P, Janeway CA Jr (1997) A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388(6640):394–397. doi:10.1038/41131 PubMedCrossRef

16.

Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282(5396):2085–2088PubMedCrossRef

17.

Poltorak A, Smirnova I, He X, Liu MY, Van Huffel C, McNally O, Birdwell D, Alejos E, Silva M, Du X, Thompson P, Chan EK, Ledesma J, Roe B, Clifton S, Vogel SN, Beutler B (1998) Genetic and physical mapping of the Lps locus: identification of the toll-4 receptor as a candidate gene in the critical region. Blood Cells Mol Dis 24(3):340–355PubMedCrossRef

18.

Kawai T, Akira S (2011) Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34(5):637–650. doi:10.1016/j.immuni.2011.05.006 PubMedCrossRef

19.

Gao H, Leaver SK, Burke-Gaffney A, Finney SJ (2008) Severe sepsis and Toll-like receptors. Semin Immunopathol 30(1):29–40. doi:10.1007/s00281-007-0101-4 PubMedCrossRef

20.

Annane D, Bellissant E, Cavaillon JM (2005) Septic shock. Lancet 365(9453):63–78. doi:10.1016/S0140-6736(04)17667-8 PubMedCrossRef

21.

Akira S, Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol 4(7):499–511. doi:10.1038/nri1391 PubMedCrossRef

22.

Armstrong L, Medford AR, Hunter KJ, Uppington KM, Millar AB (2004) Differential expression of Toll-like receptor (TLR)-2 and TLR-4 on monocytes in human sepsis. Clin Exp Immunol 136(2):312–319. doi:10.1111/j.1365-2249.2004.02433.x PubMedPubMedCentralCrossRef

23.

Harter L, Mica L, Stocker R, Trentz O, Keel M (2004) Increased expression of toll-like receptor-2 and -4 on leukocytes from patients with sepsis. Shock 22(5):403–409PubMedCrossRef

24.

Mariathasan S, Monack DM (2007) Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol 7(1):31–40. doi:10.1038/nri1997 PubMedCrossRef

25.

Zamboni DS, Kobayashi KS, Kohlsdorf T, Ogura Y, Long EM, Vance RE, Kuida K, Mariathasan S, Dixit VM, Flavell RA, Dietrich WF, Roy CR (2006) The Birc1e cytosolic pattern-recognition receptor contributes to the detection and control of Legionella pneumophila infection. Nat Immunol 7(3):318–325. doi:10.1038/ni1305 PubMedCrossRef

26.

Brown GD, Herre J, Williams DL, Willment JA, Marshall AS, Gordon S (2003) Dectin-1 mediates the biological effects of beta-glucans. J Exp Med 197(9):1119–1124. doi:10.1084/jem.20021890 PubMedPubMedCentralCrossRef

27.

Brown GD, Taylor PR, Reid DM, Willment JA, Williams DL, Martinez-Pomares L, Wong SY, Gordon S (2002) Dectin-1 is a major beta-glucan receptor on macrophages. J Exp Med 196(3):407–412PubMedPubMedCentralCrossRef

28.

Gross O, Gewies A, Finger K, Schafer M, Sparwasser T, Peschel C, Forster I, Ruland J (2006) Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature 442(7103):651–656. doi:10.1038/nature04926 PubMedCrossRef

29.

Brown GD, Gordon S (2001) Immune recognition. A new receptor for beta-glucans. Nature 413(6851):36–37. doi:10.1038/35092620 PubMedCrossRef

30.

Dennehy KM, Brown GD (2007) The role of the beta-glucan receptor Dectin-1 in control of fungal infection. J Leukoc Biol 82(2):253–258. doi:10.1189/jlb.1206753 PubMedCrossRef

31.

den Dunnen J, Gringhuis SI, Geijtenbeek TB (2009) Innate signaling by the C-type lectin DC-SIGN dictates immune responses. Cancer Immunol, Immunother 58(7):1149–1157. doi:10.1007/s00262-008-0615-1 CrossRef

32.

Fitzgerald ME, Rawling DC, Vela A, Pyle AM (2014) An evolving arsenal: viral RNA detection by RIG-I-like receptors. Curr Opin Microbiol 20:76–81. doi:10.1016/j.mib.2014.05.004 PubMedCrossRef

33.

Aird WC (2003) The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 101(10):3765–3777. doi:10.1182/blood-2002-06-1887 PubMedCrossRef

34.

Ince C, Mayeux PR, Nguyen T, Gomez H, Kellum JA, Ospina-Tascon GA, Hernandez G, Murray P, De Backer D, Workgroup AX (2016) The endothelium in sepsis. Shock 45(3):259–270. doi:10.1097/SHK.0000000000000473 PubMedPubMedCentralCrossRef

35.

Vallet B (2003) Bench-to-bedside review: endothelial cell dysfunction in severe sepsis: a role in organ dysfunction? Crit Care 7(2):130–138PubMedPubMedCentralCrossRef

36.

Sutherland AM, Walley KR (2009) Bench-to-bedside review: association of genetic variation with sepsis. Crit Care 13(2):210. doi:10.1186/cc7702 PubMedPubMedCentralCrossRef

37.

Arcaroli J, Fessler MB, Abraham E (2005) Genetic polymorphisms and sepsis. Shock 24(4):300–312PubMedCrossRef

38.

Texereau J, Pene F, Chiche JD, Rousseau C, Mira JP (2004) Importance of hemostatic gene polymorphisms for susceptibility to and outcome of severe sepsis. Crit Care Med 32(5 Suppl):S313–S319PubMedCrossRef

39.

Chung LP, Waterer GW (2011) Genetic predisposition to respiratory infection and sepsis. Crit Rev Clin Lab Sci 48(5–6):250–268. doi:10.3109/10408363.2011.641517 PubMedCrossRef

40.

Cornell TT, Wynn J, Shanley TP, Wheeler DS, Wong HR (2010) Mechanisms and regulation of the gene-expression response to sepsis. Pediatrics 125(6):1248–1258. doi:10.1542/peds.2009-3274 PubMedPubMedCentralCrossRef

41.

Mira JP, Cariou A, Grall F, Delclaux C, Losser MR, Heshmati F, Cheval C, Monchi M, Teboul JL, Riche F, Leleu G, Arbibe L, Mignon A, Delpech M, Dhainaut JF (1999) Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA 282(6):561–568PubMedCrossRef

42.

Calvano JE, Um JY, Agnese DM, Hahm SJ, Kumar A, Coyle SM, Calvano SE, Lowry SF (2003) Influence of the TNF-alpha and TNF-beta polymorphisms upon infectious risk and outcome in surgical intensive care patients. Surg Infect 4(2):163–169. doi:10.1089/109629603766956951 CrossRef

43.

Witkin SS, Gerber S, Ledger WJ (2002) Influence of interleukin-1 receptor antagonist gene polymorphism on disease. Clin Infect Dis 34(2):204–209. doi:10.1086/338261 PubMedCrossRef

44.

Arnalich F, Lopez-Maderuelo D, Codoceo R, Lopez J, Solis-Garrido LM, Capiscol C, Fernandez-Capitan C, Madero R, Montiel C (2002) Interleukin-1 receptor antagonist gene polymorphism and mortality in patients with severe sepsis. Clin Exp Immunol 127(2):331–336PubMedPubMedCentralCrossRef

45.

Meyer NJ, Ferguson JF, Feng R, Wang F, Patel PN, Li M, Xue C, Qu L, Liu Y, Boyd JH, Russell JA, Christie JD, Walley KR, Reilly MP (2014) A functional synonymous coding variant in the IL1RN gene is associated with survival in septic shock. Am J Respir Crit Care Med 190(6):656–664. doi:10.1164/rccm.201403-0586OC PubMedPubMedCentralCrossRef

46.

Surbatovic M, Grujic K, Cikota B, Jevtic M, Filipovic N, Romic P, Strelic N, Magic Z (2010) Polymorphisms of genes encoding tumor necrosis factor-alpha, interleukin-10, cluster of differentiation-14 and interleukin-1ra in critically ill patients. J Crit Care 25(3):542 e541-548. doi:10.1016/j.jcrc.2009.12.003 PubMedCrossRef

47.

Lorenz E, Mira JP, Frees KL, Schwartz DA (2002) Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 162(9):1028–1032PubMedCrossRef

48.

Wurfel MM, Gordon AC, Holden TD, Radella F, Strout J, Kajikawa O, Ruzinski JT, Rona G, Black RA, Stratton S, Jarvik GP, Hajjar AM, Nickerson DA, Rieder M, Sevransky J, Maloney JP, Moss M, Martin G, Shanholtz C, Garcia JG, Gao L, Brower R, Barnes KC, Walley KR, Russell JA, Martin TR (2008) Toll-like receptor 1 polymorphisms affect innate immune responses and outcomes in sepsis. Am J Respir Crit Care Med 178(7):710–720. doi:10.1164/rccm.200803-462OC PubMedPubMedCentralCrossRef

49.

Gallagher PM, Lowe G, Fitzgerald T, Bella A, Greene CM, McElvaney NG, O’Neill SJ (2003) Association of IL-10 polymorphism with severity of illness in community acquired pneumonia. Thorax 58(2):154–156PubMedPubMedCentralCrossRef

50.

Azab SF, Abdalhady MA, Elsaadany HF, Elkomi MA, Elhindawy EM, Sarhan DT, Salam MM, Allah MA, Emam AA, Noah MA, Abdelsalam NI, Abdellatif SH, Rass AA, Ismail SM, Gheith T, Aziz KA, Hamed ME, Abdelrahman HM, Ahmed AR, Nabil RM, Abdulmaksoud RS, Yousef HY (2016) Interleukin-10 -1082 G/A gene polymorphisms in Egyptian children with CAP: a case-control study. Medicine (Baltimore) 95(26):e4013. doi:10.1097/MD.0000000000004013 CrossRef

51.

Kolb WP, Granger GA (1968) Lymphocyte in vitro cytotoxicity: characterization of human lymphotoxin. Proc Natl Acad Sci U S A 61(4):1250–1255PubMedPubMedCentralCrossRef

52.

Ruddle NH, Waksman BH (1967) Cytotoxic effect of lymphocyte-antigen interaction in delayed hypersensitivity. Science 157(3792):1060–1062PubMedCrossRef

53.

Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 72(9):3666–3670PubMedPubMedCentralCrossRef

54.

Beutler B, Greenwald D, Hulmes JD, Chang M, Pan YC, Mathison J, Ulevitch R, Cerami A (1985) Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 316(6028):552–554PubMedCrossRef

55.

Clark IA, Cowden WB (1989) Is TNF a key to acute infectious illness? Today’s Life Sci 1:26–29

56.

Clark IA, Virelizier JL, Carswell EA, Wood PR (1981) Possible importance of macrophage-derived mediators in acute malaria. Infect Immun 32(3):1058–1066PubMedPubMedCentral

57.

Clark IA (1982) Suggested importance of monokines in pathophysiology of endotoxin shock and malaria. Klin Wochenschr 60(14):756–758PubMedCrossRef

58.

Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ 3rd, Zentella A, Albert JD et al (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234(4775):470–474PubMedCrossRef

59.

Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330(6149):662–664. doi:10.1038/330662a0 PubMedCrossRef

60.

Tracey KJ, Cerami A (1989) Cachectin/tumor necrosis factor and other cytokines in infectious disease. Curr Opin Immunol 1(3):454–461PubMedCrossRef

61.

Dinarello CA (2007) Historical insights into cytokines. Eur J Immunol 37(Suppl 1):S34–S45. doi:10.1002/eji.200737772 PubMedPubMedCentralCrossRef

62.

Weber A, Wasiliew P, Kracht M (2010) Interleukin-1 (IL-1) pathway. Sci Signal 3(105):cm1. doi:10.1126/scisignal.3105cm1 PubMed

63.

Mera S, Tatulescu D, Cismaru C, Bondor C, Slavcovici A, Zanc V, Carstina D, Oltean M (2011) Multiplex cytokine profiling in patients with sepsis. APMIS 119(2):155–163. doi:10.1111/j.1600-0463.2010.02705.x PubMedCrossRef

64.

Jones SA, Scheller J, Rose-John S (2011) Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 121(9):3375–3383. doi:10.1172/JCI57158 PubMedPubMedCentralCrossRef

65.

Gouel-Cheron A, Allaouchiche B, Guignant C, Davin F, Floccard B, Monneret G, AzuRea G (2012) Early interleukin-6 and slope of monocyte human leukocyte antigen-DR: a powerful association to predict the development of sepsis after major trauma. PLoS One 7(3):e33095. doi:10.1371/journal.pone.0033095 PubMedPubMedCentralCrossRef

66.

Wu HP, Chen CK, Chung K, Tseng JC, Hua CC, Liu YC, Chuang DY, Yang CH (2009) Serial cytokine levels in patients with severe sepsis. Inflamm Res 58(7):385–393. doi:10.1007/s00011-009-0003-0 PubMedCrossRef

67.

Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, Fine J, Krichevsky A, Delude RL, Angus DC, Gen IMSI (2007) Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 167(15):1655–1663. doi:10.1001/archinte.167.15.1655 PubMedPubMedCentralCrossRef

68.

Riedemann NC, Guo RF, Hollmann TJ, Gao H, Neff TA, Reuben JS, Speyer CL, Sarma JV, Wetsel RA, Zetoune FS, Ward PA (2004) Regulatory role of C5a in LPS-induced IL-6 production by neutrophils during sepsis. FASEB J 18(2):370–372. doi:10.1096/fj.03-0708fje PubMed

69.

Riedemann NC, Neff TA, Guo RF, Bernacki KD, Laudes IJ, Sarma JV, Lambris JD, Ward PA (2003) Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J Immunol 170(1):503–507PubMedCrossRef

70.

Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM (2001) The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 15(1):43–58. doi:10.1096/fj.99-1003rev PubMedCrossRef

71.

Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O’Garra A, Murphy KM (1993) Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260(5107):547–549PubMedCrossRef

72.

Costa VS, Mattana TC, da Silva ME (2010) Unregulated IL-23/IL-17 immune response in autoimmune diseases. Diabetes Res Clin Pract 88(3):222–226. doi:10.1016/j.diabres.2010.03.014 PubMedCrossRef

73.

Reynolds JM, Angkasekwinai P, Dong C (2010) IL-17 family member cytokines: regulation and function in innate immunity. Cytokine Growth Factor Rev 21(6):413–423. doi:10.1016/j.cytogfr.2010.10.002 PubMedPubMedCentralCrossRef

74.

Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B (2006) TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24(2):179–189. doi:10.1016/j.immuni.2006.01.001 PubMedCrossRef

75.

McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, McClanahan T, Cua DJ (2007) TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 8(12):1390–1397. doi:10.1038/ni1539 PubMedCrossRef

76.

Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB, Oukka M, Kuchroo VK (2007) IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 448(7152):484–487. doi:10.1038/nature05970 PubMedPubMedCentralCrossRef

77.

Manel N, Unutmaz D, Littman DR (2008) The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 9(6):641–649. doi:10.1038/ni.1610 PubMedPubMedCentralCrossRef

78.

Schroder K, Hertzog PJ, Ravasi T, Hume DA (2004) Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75(2):163–189. doi:10.1189/jlb.0603252 PubMedCrossRef

79.

Schoenborn JR, Wilson CB (2007) Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 96:41–101. doi:10.1016/S0065-2776(07)96002-2 PubMedCrossRef

80.

Romero CR, Herzig DS, Etogo A, Nunez J, Mahmoudizad R, Fang G, Murphey ED, Toliver-Kinsky T, Sherwood ER (2010) The role of interferon-gamma in the pathogenesis of acute intra-abdominal sepsis. J Leukoc Biol 88(4):725–735. doi:10.1189/jlb.0509307 PubMedPubMedCentralCrossRef

81.

Ono S, Ueno C, Aosasa S, Tsujimoto H, Seki S, Mochizuki H (2001) Severe sepsis induces deficient interferon-gamma and interleukin-12 production, but interleukin-12 therapy improves survival in peritonitis. Am J Surg 182(5):491–497PubMedCrossRef

82.

Cai S, Batra S, Lira SA, Kolls JK, Jeyaseelan S (2010) CXCL1 regulates pulmonary host defense to Klebsiella infection via CXCL2, CXCL5, NF-kappaB, and MAPKs. J Immunol 185(10):6214–6225. doi:10.4049/jimmunol.0903843 PubMedPubMedCentralCrossRef

83.

Robben PM, LaRegina M, Kuziel WA, Sibley LD (2005) Recruitment of Gr-1+ monocytes is essential for control of acute toxoplasmosis. J Exp Med 201(11):1761–1769. doi:10.1084/jem.20050054 PubMedPubMedCentralCrossRef

84.

Lionakis MS, Swamydas M, Fischer BG, Plantinga TS, Johnson MD, Jaeger M, Green NM, Masedunskas A, Weigert R, Mikelis C, Wan W, Lee CC, Lim JK, Rivollier A, Yang JC, Laird GM, Wheeler RT, Alexander BD, Perfect JR, Gao JL, Kullberg BJ, Netea MG, Murphy PM (2013) CX3CR1-dependent renal macrophage survival promotes Candida control and host survival. J Clin Invest 123(12):5035–5051. doi:10.1172/JCI71307 PubMedPubMedCentralCrossRef

85.

Chousterman BG, Boissonnas A, Poupel L, Baudesson de Chanville C, Adam J, Tabibzadeh N, Licata F, Lukaszewicz AC, Lombes A, Deterre P, Payen D, Combadiere C (2016) Ly6Chigh monocytes protect against kidney damage during sepsis via a CX3CR1-dependent adhesion mechanism. J Am Soc Nephrol 27(3):792–803. doi:10.1681/ASN.2015010009 PubMedCrossRef

86.

Hamilton JA (2008) Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 8(7):533–544. doi:10.1038/nri2356 PubMedCrossRef

87.

Rauch PJ, Chudnovskiy A, Robbins CS, Weber GF, Etzrodt M, Hilgendorf I, Tiglao E, Figueiredo JL, Iwamoto Y, Theurl I, Gorbatov R, Waring MT, Chicoine AT, Mouded M, Pittet MJ, Nahrendorf M, Weissleder R, Swirski FK (2012) Innate response activator B cells protect against microbial sepsis. Science 335(6068):597–601. doi:10.1126/science.1215173 PubMedPubMedCentralCrossRef

88.

Schreuder H, Tardif C, Trump-Kallmeyer S, Soffientini A, Sarubbi E, Akeson A, Bowlin T, Yanofsky S, Barrett RW (1997) A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist. Nature 386(6621):194–200. doi:10.1038/386194a0 PubMedCrossRef

89.

Dinarello CA (1997) Induction of interleukin-1 and interleukin-1 receptor antagonist. Semin Oncol 24(3 Suppl 9):S9-81–S89-93

90.

Alexander HR, Doherty GM, Venzon DJ, Merino MJ, Fraker DL, Norton JA (1992) Recombinant interleukin-1 receptor antagonist (IL-1ra): effective therapy against gram-negative sepsis in rats. Surgery 112(2):188–193 discussion 193-184 PubMed

91.

Herold S, Tabar TS, Janssen H, Hoegner K, Cabanski M, Lewe-Schlosser P, Albrecht J, Driever F, Vadasz I, Seeger W, Steinmueller M, Lohmeyer J (2011) Exudate macrophages attenuate lung injury by the release of IL-1 receptor antagonist in gram-negative pneumonia. Am J Respir Crit Care Med 183(10):1380–1390. doi:10.1164/rccm.201009-1431OC PubMedCrossRef

92.

Wynn TA (2015) Type 2 cytokines: mechanisms and therapeutic strategies. Nat Rev Immunol 15(5):271–282. doi:10.1038/nri3831 PubMedCrossRef

93.

Luzina IG, Keegan AD, Heller NM, Rook GA, Shea-Donohue T, Atamas SP (2012) Regulation of inflammation by interleukin-4: a review of “alternatives”. J Leukoc Biol 92(4):753–764. doi:10.1189/jlb.0412214 PubMedPubMedCentralCrossRef

94.

Couper KN, Blount DG, Riley EM (2008) IL-10: the master regulator of immunity to infection. J Immunol 180(9):5771–5777PubMedCrossRef

95.

Opal SM, DePalo VA (2000) Anti-inflammatory cytokines. Chest 117(4):1162–1172PubMedCrossRef

96.

Hotchkiss RS, Monneret G, Payen D (2013) Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 13(12):862–874. doi:10.1038/nri3552 PubMedPubMedCentralCrossRef

97.

Yang YC, Ciarletta AB, Temple PA, Chung MP, Kovacic S, Witek-Giannotti JS, Leary AC, Kriz R, Donahue RE, Wong GG et al (1986) Human IL-3 (multi-CSF): identification by expression cloning of a novel hematopoietic growth factor related to murine IL-3. Cell 47(1):3–10PubMedCrossRef

98.

Weber GF, Chousterman BG, He S, Fenn AM, Nairz M, Anzai A, Brenner T, Uhle F, Iwamoto Y, Robbins CS, Noiret L, Maier SL, Zonnchen T, Rahbari NN, Scholch S, Klotzsche-von Ameln A, Chavakis T, Weitz J, Hofer S, Weigand MA, Nahrendorf M, Weissleder R, Swirski FK (2015) Interleukin-3 amplifies acute inflammation and is a potential therapeutic target in sepsis. Science 347(6227):1260–1265. doi:10.1126/science.aaa4268 PubMedPubMedCentralCrossRef

99.

Bentzer P, Fjell C, Walley KR, Boyd J, Russell JA (2016) Plasma cytokine levels predict response to corticosteroids in septic shock. Intensive Care Med 42(12):1970–1979. doi:10.1007/s00134-016-4338-z PubMedCrossRef

100.

Copeland S, Warren HS, Lowry SF, Calvano SE, Remick D, Inflammation, the Host Response to Injury I (2005) Acute inflammatory response to endotoxin in mice and humans. Clin Diagn Lab Immunol 12(1):60–67. doi:10.1128/CDLI.12.1.60-67.2005 PubMedPubMedCentral

101.

Bahador M, Cross AS (2007) From therapy to experimental model: a hundred years of endotoxin administration to human subjects. J Endotoxin Res 13(5):251–279. doi:10.1177/0968051907085986 PubMedCrossRef

102.

Dorresteijn MJ, Visser T, Cox LA, Bouw MP, Pillay J, Koenderman AH, Strengers PF, Leenen LP, van der Hoeven JG, Koenderman L, Pickkers P (2010) C1-esterase inhibitor attenuates the inflammatory response during human endotoxemia. Crit Care Med 38(11):2139–2145. doi:10.1097/CCM.0b013e3181f17be4 PubMedCrossRef

103.

van Deventer SJ, Buller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A (1990) Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 76(12):2520–2526PubMed

104.

Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, Chen RO, Brownstein BH, Cobb JP, Tschoeke SK, Miller-Graziano C, Moldawer LL, Mindrinos MN, Davis RW, Tompkins RG, Lowry SF, Inflamm, Host Response to Injury Large Scale Collab. Res P (2005) A network-based analysis of systemic inflammation in humans. Nature 437(7061):1032–1037. doi:10.1038/nature03985 PubMedCrossRef

105.

Shalova IN, Lim JY, Chittezhath M, Zinkernagel AS, Beasley F, Hernandez-Jimenez E, Toledano V, Cubillos-Zapata C, Rapisarda A, Chen J, Duan K, Yang H, Poidinger M, Melillo G, Nizet V, Arnalich F, Lopez-Collazo E, Biswas SK (2015) Human monocytes undergo functional re-programming during sepsis mediated by hypoxia-inducible factor-1alpha. Immunity 42(3):484–498. doi:10.1016/j.immuni.2015.02.001 PubMedCrossRef

106.

Cazalis MA, Lepape A, Venet F, Frager F, Mougin B, Vallin H, Paye M, Pachot A, Monneret G (2014) Early and dynamic changes in gene expression in septic shock patients: a genome-wide approach. Intensive Care Med Exp 2(1):20. doi:10.1186/s40635-014-0020-3 PubMedPubMedCentralCrossRef

107.

Payen D, Lukaszewicz AC, Belikova I, Faivre V, Gelin C, Russwurm S, Launay JM, Sevenet N (2008) Gene profiling in human blood leucocytes during recovery from septic shock. Intensive Care Med 34(8):1371–1376. doi:10.1007/s00134-008-1048-1 PubMedCrossRef

108.

Opal SM, Dellinger RP, Vincent JL, Masur H, Angus DC (2014) The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C?*. Crit Care Med 42(7):1714–1721. doi:10.1097/CCM.0000000000000325 PubMedPubMedCentralCrossRef

109.

Hahn EO, Houser HB, Rammelkamp CH Jr, Denny FW, Wannamaker LW (1951) Effect of cortisone on acute streptococcal infections and poststreptococcal complications. J Clin Invest 30(3):274–281. doi:10.1172/JCI102441 PubMedPubMedCentralCrossRef

110.

Rhen T, Cidlowski JA (2005) Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. N Engl J Med 353(16):1711–1723. doi:10.1056/NEJMra050541 PubMedCrossRef

111.

Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, Chaumet-Riffaud P, Bellissant E (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288(7):862–871PubMedCrossRef

112.

Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre PF, Reinhart K, Cuthbertson BH, Payen D, Briegel J, Group CS (2008) Hydrocortisone therapy for patients with septic shock. N Engl J Med 358(2):111–124. doi:10.1056/NEJMoa071366 PubMedCrossRef

113.

Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, Shelly MP, Pribble JP, LaBrecque JF, Lookabaugh J, Donovan H, Dubin H, Baughman R, Norman J, DeMaria E, Matzel K, Abraham E, Seneff M (1997) Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 25(7):1115–1124PubMedCrossRef

114.

Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, Wittebole X, Dugernier T, Perrotin D, Tidswell M, Jauregui L, Krell K, Pachl J, Takahashi T, Peckelsen C, Cordasco E, Chang CS, Oeyen S, Aikawa N, Maruyama T, Schein R, Kalil AC, Van Nuffelen M, Lynn M, Rossignol DP, Gogate J, Roberts MB, Wheeler JL, Vincent JL, Group AS (2013) Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 309(11):1154–1162. doi:10.1001/jama.2013.2194 PubMedCrossRef

115.

Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R et al (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 273(12):934–941PubMedCrossRef

116.

McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR (1994) Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 121(1):1–5PubMedCrossRef

117.

Payen DM, Guilhot J, Launey Y, Lukaszewicz AC, Kaaki M, Veber B, Pottecher J, Joannes-Boyau O, Martin-Lefevre L, Jabaudon M, Mimoz O, Coudroy R, Ferrandiere M, Kipnis E, Vela C, Chevallier S, Mallat J, Robert R, Group A (2015) Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med 41(6):975–984. doi:10.1007/s00134-015-3751-z PubMedPubMedCentralCrossRef

118.

Qiu P, Cui X, Sun J, Welsh J, Natanson C, Eichacker PQ (2013) Antitumor necrosis factor therapy is associated with improved survival in clinical sepsis trials: a meta-analysis. Crit Care Med 41(10):2419–2429. doi:10.1097/CCM.0b013e3182982add PubMedCrossRef

119.

Schouten M, Wiersinga WJ, Levi M, van der Poll T (2008) Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 83(3):536–545. doi:10.1189/jlb.0607373 PubMedCrossRef

120.

Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr, Recombinant human protein CWEiSSsg (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344(10):699–709. doi:10.1056/NEJM200103083441001 PubMedCrossRef

121.

Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gardlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD, Group P-SS (2012) Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 366(22):2055–2064. doi:10.1056/NEJMoa1202290 PubMedCrossRef

122.

London NR, Zhu W, Bozza FA, Smith MC, Greif DM, Sorensen LK, Chen L, Kaminoh Y, Chan AC, Passi SF, Day CW, Barnard DL, Zimmerman GA, Krasnow MA, Li DY (2010) Targeting Robo4-dependent Slit signaling to survive the cytokine storm in sepsis and influenza. Sci Transl Med 2(23):23ra19. doi:10.1126/scitranslmed.3000678 PubMedPubMedCentralCrossRef

123.

Zhao H, Anand AR, Ganju RK (2014) Slit2-Robo4 pathway modulates lipopolysaccharide-induced endothelial inflammation and its expression is dysregulated during endotoxemia. J Immunol 192(1):385–393. doi:10.4049/jimmunol.1302021 PubMedCrossRef

124.

Maceyka M, Harikumar KB, Milstien S, Spiegel S (2012) Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol 22(1):50–60. doi:10.1016/j.tcb.2011.09.003 PubMedCrossRef

125.

Teijaro JR, Walsh KB, Cahalan S, Fremgen DM, Roberts E, Scott F, Martinborough E, Peach R, Oldstone MB, Rosen H (2011) Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 146(6):980–991. doi:10.1016/j.cell.2011.08.015 PubMedPubMedCentralCrossRef

Title: Cytokine storm and sepsis disease pathogenesis
Authors: Benjamin G. Chousterman
Filip K. Swirski
Georg F. Weber
Publication date: 01-07-2017
Publisher: Springer Berlin Heidelberg
Published in: Seminars in Immunopathology / Issue 5/2017
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-017-0639-8

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Cytokine storm and sepsis disease pathogenesis

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2017

New fronts emerge in the influenza cytokine storm

The meteorology of cytokine storms, and the clinical usefulness of this knowledge

Cytokine storms in infectious diseases

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

Immune-mediated cytokine storm and its role in severe dengue

Molecular pathogenesis of viral hemorrhagic fever

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page